Page 122 - Read Online

Page 22 of 23 Thonglert et al. Hepatoma Res 2023;9:40 https://dx.doi.org/10.20517/2394-5079.2023.47

55. Ruan JL, Lee C, Wouters S, et al. Irradiation at ultra-high (FLASH) dose rates reduces acute normal tissue toxicity in the mouse
gastrointestinal system. Int J Radiat Oncol Biol Phys 2021;111:1250-61. DOI PubMed PMC
56. Mascia AE, Daugherty EC, Zhang Y, et al. Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-
01 nonrandomized trial. JAMA Oncol 2023;9:62-9. DOI PubMed PMC
57. Raaymakers BW, Lagendijk JJ, Overweg J, et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys
Med Biol 2009;54:N229-37. DOI
58. Mutic S, Dempsey JF. The viewray system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 2014;24:196-
9. DOI PubMed
59. Raaymakers BW, Jürgenliemk-Schulz IM, Bol GH, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a
high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 2017;62:L41-50. DOI
60. Rogowski P, von Bestenbostel R, Walter F, et al. Feasibility and early clinical experience of online adaptive mr-guided radiotherapy of
liver tumors. Cancers 2021;13:1523. DOI PubMed PMC
61. Klüter S, Katayama S, Spindeldreier CK, et al. First prospective clinical evaluation of feasibility and patient acceptance of magnetic
resonance-guided radiotherapy in Germany. Strahlenther Onkol 2020;196:691-8. DOI PubMed PMC
62. Corradini S, Alongi F, Andratschke N, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives.
Radiat Oncol 2019;14:92. DOI PubMed PMC
63. Noel CE, Parikh PJ, Spencer CR, et al. Comparison of onboard low-field magnetic resonance imaging versus onboard computed
tomography for anatomy visualization in radiotherapy. Acta Oncol 2015;54:1474-82. DOI
64. Kurz C, Buizza G, Landry G, et al. Medical physics challenges in clinical MR-guided radiotherapy. Radiat Oncol 2020;15:93. DOI
PubMed PMC
65. Mittauer K, Paliwal B, Hill P, et al. A new era of image guidance with magnetic resonance-guided radiation therapy for abdominal and
thoracic malignancies. Cureus 2018;10:e2422. DOI PubMed PMC
66. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the
treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 2018;126:519-26. DOI PubMed
67. Feldman AM, Modh A, Glide-Hurst C, Chetty IJ, Movsas B. Real-time magnetic resonance-guided liver stereotactic body radiation
therapy: an institutional report using a magnetic resonance-linac system. Cureus 2019;11:e5774. DOI PubMed PMC
68. Luterstein E, Cao M, Lamb JM, et al. Clinical outcomes using magnetic resonance-guided stereotactic body radiation therapy in
patients with locally advanced cholangiocarcinoma. Adv Radiat Oncol 2019;5:189-95. DOI PubMed PMC
69. Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of mr-guided liver stereotactic body radiation therapy.
Adv Radiat Oncol 2019;4:142-9. DOI PubMed PMC
70. Chin RI, Schiff JP, Bommireddy A, et al. Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided
stereotactic body radiation therapy: a Six-Year experience. Clin Transl Radiat Oncol 2023;41:100627. DOI PubMed PMC
71. Lamb J, Cao M, Kishan A, et al. Online adaptive radiation therapy: implementation of a new process of care. Cureus 2017;9:e1618.
DOI PubMed PMC
72. Hall WA, Paulson E, Li XA, et al. Magnetic resonance linear accelerator technology and adaptive radiation therapy: an overview for
clinicians. CA Cancer J Clin 2022;72:34-56. DOI PubMed PMC
73. Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol
2020;21:e74-82. DOI PubMed
74. Ding J, Zhang Y, Amjad A, et al. Deep learning based automatic contour refinement for inaccurate auto-segmentation in MR-guided
adaptive radiotherapy. Phys Med Biol 2023;68:055004. DOI PubMed PMC
75. Güngör G, Serbez İ, Temur B, et al. Time analysis of online adaptive magnetic resonance-guided radiation therapy workflow
according to anatomical sites. Pract Radiat Oncol 2021;11:e11-21. DOI
76. van Houdt PJ, Yang Y, van der Heide UA, et al. Quantitative magnetic resonance imaging for biological image-guided adaptive
radiotherapy. Front Oncol 2020;10:615643. DOI PubMed PMC
77. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-
positive intrahepatic cholangiocarcinoma. Cancer Discov 2019;9:1064-79. DOI
78. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic
cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Lancet Gastroenterol Hepatol 2021;6:803-15. DOI PubMed
79. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma:
a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84. DOI PubMed PMC
80. Goyal L, Meric-Bernstam F, Hollebecque A, et al; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-rearranged intrahepatic
cholangiocarcinoma. N Engl J Med 2023;388:228-39. DOI
81. Ahmed MA, Selzer E, Dörr W, et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
Oncotarget 2016;7:69976-90. DOI PubMed PMC
82. Nuryadi E, Sasaki Y, Hagiwara Y, et al. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Oncotarget 2018;9:32642-52. DOI PubMed PMC
83. Yoshimoto Y, Sasaki Y, Murata K, et al. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Gynecol Oncol 2020;159:546-53. DOI